Abstract: The present invention relates to a method of identifying one or more T cells, as well as method of isolating one or more T cells. Further, the invention relates to a method of identifying one or more TCR, a nucleic acid molecule comprising a nucleic acid sequence encoding the TCR identified by the methods of the invention. The invention also relates to a method of generating one or more immune cells. The invention also relates to a host cell comprising a nucleic molecule encoding a TCR identified by the invention or generated by a method of the invention. The invention also relates to a pharmaceutical composition comprising a cell of the invention, or a cell of the invention for use in therapy. Finally, the invention also relates to a method of diagnosing cancer.

Abstract: The present invention relates to a method for treating cancer in a subject, comprising the step of administering to a subject in need thereof administering a therapeutically effective dose of a T cell capable of binding a neopeptide that is expressed by a tumor suppressor gene, wherein said neopeptide is derived from a frameshift product of a tumor suppressor gene and wherein the T cell binds to the neopeptide-MHC complex with a half-life (T1/2) of at least 50 s.

Abstract: The present invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T½) of at least 50 s with a neopeptide-MHC monomer. The present invention further relates to a T cell obtainable by the method as well as a pharmaceutical composition comprising such T cells.

Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.

Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.

Abstract: The present invention relates to a peptide comprising a reversible affinity tag (A); and a functionalization tag (F), wherein the peptide is linked to a target of interest (T). The peptide is useful as a versatile protein tag. The invention further provides structures comprising the peptide, nucleic acids, vectors, and host cells. Further, the invention provides methods of producing or using the peptide.

Abstract: The present disclosure provides tag-specific fusion proteins for selectively detecting molecules containing a strep-tag peptide or cells containing a strep-tag peptide. Disclosed embodiments include tag-specific fusion proteins that can be used in reagents and methods for monitoring and/or modulating immunotherapy cells that express a strep-tag peptide. Embodiments including fusion proteins that specifically bind tagged targets and recombinant host cells comprising polynucleotides encoding the tag-specific fusion proteins are also provided. Immunotherapy cells that express a tagged marker are also provided.

Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.

Abstract: The present invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T½) of at least 50 s with a neopeptide-MHC monomer. The present invention further relates to a T cell obtainable by the method as well as a pharmaceutical composition comprising such T cells.

Abstract: The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.

Abstract: The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.

Abstract: The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.

Abstract: The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.

Abstract: The invention relates to MHC tetramer fusion proteins, MHC monomer fusion proteins, DNA encoding a MHC fusion protein as well as RNA yielding after transcription a MHC monomer fusion protein. Furthermore, the invention discloses the use of a DsRed protein as an agent for the tetramerization of MHC molecules, methods for the preparation of fusion proteins containing MHC and DsRed, and methods for the preparation of MHC tetramers. Moreover, the invention describes methods for the examination of an antigen-specific cellular immune response, particularly for the detection of T lymphocytes carrying specific T cell receptors on their surfaces, the uses of the MHC monomers and tetramers prepared according to the invention as well as test systems containing the MHC monomers or MHC tetramers according to the invention.